OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer
The webcast replay of the General Assembly Meeting of September 30, 2025 (in French), is available: click here